Lantern Pharma Inc. (LTRN) Form 10-Q — May 15, 2026
Lantern Pharma reported a net loss of $3.3 million for the first quarter of 2026, driven by $1.7 million in R&D expenses and $1.7 million in general and administrative costs. The company holds approximately $6.3 million in cash and marketable securities but explicitly states that these factors raise substantial doubt about its ability to continue as a going concern without additional funding. To address liquidity needs, Lantern Pharma closed a registered direct offering on May 14, 2026, raising approximately $4.4 million in gross proceeds.
Key figures
- Total Assets
- 7057260
- Cash Position
- 4917796
- Shares Outstanding
- 11304697
- Ga Expenses
- 1680375
- Rd Expenses
- 1724872
- Offering Price
- 2.06
- Shares Offered
- 1454175
- Warrants Issued
- 2135923
- Working Capital
- 3280000
- Offering Proceeds
- 4400000
- Pre Funded Warrants
- 681748
- Marketable Securities
- 1405057
- Warrant Exercise Price
- 2.27
Price after filing
Close on the filing date to close N calendar days later (from $3.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.